8.17

2.51% 0.20

After Hours: 8.21 0.04 +0.49%

Oric Pharmaceuticals Inc (ORIC)

Overview News Price History Option Chain Financials Discussions Forecast

Oric Pharmaceuticals Inc stock is traded at $8.17, with a volume of 3.62M. It is up +2.51% in the last 24 hours and up +44.47% over the past month. ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Previous Close:

$7.97

Open:

$7.62

24h Volume:

3.62M

Relative Volume:

3.53

Market Cap:

$580.81M

Revenue:

Net Income/Loss:

$-119.87M

P/E Ratio:

-4.5138

EPS:

-1.81

Net Cash Flow:

$-109.90M

1W Performance:

+28.66%

1M Performance:

+44.47%

6M Performance:

-17.47%

1Y Performance:

-8.51%

1-Day Range:

$7.46

$8.40

1-Week Range:

$5.5148

$8.439

52-Week Range:

$3.8951

$14.67

Oric Pharmaceuticals Inc Stock (ORIC) Company Profile

Name

Oric Pharmaceuticals Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(650) 388-5600

Address

240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA

Employee

122

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

ORIC's Discussions on Twitter

Compare ORIC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ORIC Oric Pharmaceuticals Inc	8.17	451.41M	0	-119.87M	-109.90M	-1.81
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-31-24	Initiated	Wells Fargo	Overweight
Sep-06-24	Initiated	Stifel	Buy
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-06-21	Upgrade	Citigroup	Neutral → Buy
Jan-25-21	Downgrade	Citigroup	Buy → Neutral
Aug-13-20	Initiated	Robert W. Baird	Outperform
Aug-06-20	Upgrade	Citigroup	Neutral → Buy
Aug-03-20	Initiated	H.C. Wainwright	Buy
May-19-20	Initiated	Citigroup	Neutral
May-19-20	Initiated	Guggenheim	Buy
May-19-20	Initiated	JP Morgan	Overweight
May-19-20	Initiated	Jefferies	Buy

View All

Oric Pharmaceuticals Inc Stock (ORIC) Latest News

12:19 PM

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownWhat's Next? - MarketBeat

12:19 PM

May 30, 2025

ORIC-944 shows promise in combination with AR inhibitors in mCRPC - Urology Times

May 30, 2025

Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC) - MarketBeat

May 30, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpShould You Buy? - MarketBeat

May 30, 2025

Deutsche Bank AG Has $464,000 Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World

May 30, 2025

ORIC Pharmaceuticals (NASDAQ:ORIC) Given “Outperform” Rating at Wedbush - Defense World

May 30, 2025

Traders Buy Large Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC) - Defense World

May 30, 2025

Oric Pharma Stock Hits 3-Month High On Promising Results In Prostate Cancer Trial - Asianet Newsable

May 30, 2025

May 29, 2025